Liquidia Stock (NASDAQ:LQDA)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$67.68

52W Range

$21.15 - $93.61

50D Avg

$78.16

200D Avg

$51.74

Market Cap

$6.15B

Avg Vol (3M)

$1.77M

Beta

0.54

Div Yield

-

LQDA Company Profile

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

216

IPO Date

Jul 26, 2018

Website

LQDA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 20
Product	$148.29M	-
Service	$10.03M	-
Promotion Agreement	-	$739.63K
Research and Development Services	-	-

Fiscal year ends in Dec 25 | Currency in USD

LQDA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$158.32M	$14.00M	$17.49M
Operating Income	$-51.38M	$-121.29M	$-73.38M
Net Income	$-68.92M	$-130.39M	$-78.50M
EBITDA	$-51.38M	$-115.71M	$-70.05M
Basic EPS	$-0.80	$-1.66	$-1.21
Diluted EPS	$-0.80	$-1.66	$-1.21

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 12, 26 | 8:30 AM

Q1 26May 11, 26 | 8:30 AM

Q4 25Mar 05, 26 | 8:30 AM

Peer Comparison

Ticker	Company
GLPG	Galapagos N.V.
RCUS	Arcus Biosciences, Inc.
GPCR	Structure Therapeutics Inc.
COGT	Cogent Biosciences, Inc.
AGIO	Agios Pharmaceuticals, Inc.
IBRX	ImmunityBio, Inc.
MESO	Mesoblast Limited
DNLI	Denali Therapeutics Inc.
OCUL	Ocular Therapeutix, Inc.